Clinical course of pharyngotonsillitis with group A streptococcus treated with different penicillin V strategies, divided in groups of Centor Score 3 and 4: a prospective study in primary care

David Tell1*, Mia Tyrstrup2, Charlotta Edlund3, Karin Rystedt4,5,6, Gunilla Skoog Ståhlgren3, Pär-Daniel Sundvall4,5,6 and Katarina Hedin1,2

Abstract

Background: Sore throat is a common reason for prescribing antibiotics in primary care, and 10 days of treatment is recommended for patients with pharyngotonsillitis with group A streptococcus (GAS). Our group recently showed that penicillin V (PcV) four times daily for 5 days was non-inferior in clinical outcome to PcV three times daily for 10 days. This study compares duration, intensity of symptoms, and side effects in patients with a Centor Score (CS) of 3 or 4 respectively, after treatment with PcV for 5 or 10 days and evaluates whether all patients with pharyngotonsillitis with a CS of 3 or 4 should be treated for 5 days or if severity of symptoms or CS suggest a longer treatment period.

Method: Data on symptoms and recovery from patient diaries from 433 patients included in a RCT comparing PcV 800 mg × 4 for 5 days or PcV 1 g × 3 for 10 days was used. Patients six years and older with CS-3 or CS-4 and positive rapid antigen detection test for GAS-infection were grouped based on CS and randomized treatment. Comparisons for categorical variables were made with Pearson's chi-squared test or Fisher’s exact test. Continuous variables were compared with the Mann–Whitney U test.

Results: Patients with CS-3 as well as patients with CS-4 who received PcV 800 mg × 4 for 5 days self-reported that they recovered earlier compared to patients with CS-3 or CS-4 who received treatment with PcV 1 g × 3 for 10 days. In addition, the throat pain as single symptom was relieved 1 day earlier in patients with CS-4 and 5 days of treatment compared to patients with CS-4 and 10 days of treatment. No differences in side effects between the groups were found.

Conclusion: Intense treatment with PcV four times a day for 5 days seems clinically beneficial and strengthens the suggestion that the 4-dose regimen with 800 mg PcV for 5 days may be the future treatment strategy for GAS positive pharyngotonsillitis irrespectively of CS-3 or CS-4.

Trail registration ClinicalTrials.gov ID: NCT02712307 (3 April 2016).
Background

Antibiotic resistance is of great concern and the use of antibiotics is the major force driving resistance [1]. The number of consultations and the prescribing rate of antibiotics for respiratory tract infections differs between countries [2]. A common reason for prescribing antibiotics is sore throat. In 2013, approximately 18 prescriptions per 1000 patients were due to sore throat, accounting for about 11% of all antibiotic prescriptions in primary health care in Sweden [3].

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Sore Throat Guideline Group [4] and the Swedish national guidelines [5] recommend using Centor criteria (fever, tender cervical lymph nodes, coatings of the tonsils, and lack of cough) [6] to identify patients who have a higher likelihood of group A streptococcus (GAS) infection. This group (i.e., CS-3 and CS-4) is more likely to benefit from antimicrobial treatment [4, 5]. Patients with CS-3 or CS-4 should be offered antibiotic treatment if they have a positive rapid antigen detection test (RADT) for GAS [4–6].

A Cochrane report from 2012 recommends 10 days treatment with penicillin [7], and a review from 2020 concluded that long-course phenoxymethylpenicillin (PcV) should remain as the first line antibiotic for the treatment of patients with streptococcal pharyngitis. In this review, most studies compared long-term antibiotic treatment of patients with streptococcal pharyngitis, a CS of 3 or 4 and positive RADT for GAS were randomized to either PcV 800 mg × 4 for 5 days or PcV 1 g × 3 for 10 days. Patients were excluded if they had signs of serious illness, had hypersensitivity to penicillin, were receiving immunomodulation treatment corresponding to at least 15 mg of prednisolone, had received antibiotics for pharyngotonsillitis in the past month, or had received any antibiotic treatment within 72 h before inclusion [10]. The patients (or guardian) registered symptoms, intensity of symptoms, and side effects in a diary until a follow-up visit 5 to 7 days after end of treatment. During a follow-up telephone call one month after completion of antibiotic treatment, regional study nurses asked the participants if they were experiencing throat symptoms, relapses, or new tonsillitis, complications, and adverse events. Throat swabs for RADT and culture for GAS identification were performed at the inclusion visit and at the follow-up visit. The same procedures were performed in the groups. Patients were recruited from 17 primary healthcare centres in urban and rural regions of Sweden.

GAS isolates were sent to the local microbiological laboratory for culturing and then to the Public Health Agency of Sweden. At the Public Health Agency of Sweden, GAS isolates from patients without bacteriological eradication at the follow-up visit and with an available isolate from the inclusion visit were emm typed [11] so pairwise relatedness within patients could be determined.

In the present study, the 422 patients from the modified intention to treat population were included [10], except two patients who did not have a CS of 3 or 4, so the final sample was 420 patients. These patients were grouped based on CS (CS-3 or CS-4) and randomized treatment (PcV 800 mg × 4 for 5 days or PcV 1 g × 3 for 10 days). We used data from the patient diaries to assess time to self-reported recovery from infection, return to work/school or equivalent, relief of fever, number of days using painkillers, and throat symptoms (no symptoms, mild, moderate, or severe symptoms). In addition, we analysed occurrence of side effects and number of days with reported side effects such as diarrhoea, nausea/vomiting, vaginal itching or discharge, and rash. We compared the number of days of the above variables between the four groups.

Two of the authors (DT, KH) discussed and classified the patients with incomplete diaries, missing data, and
deviations in answers. Patients with incomplete registrations on the question 'Do you consider yourself or your child recovered from the current infection' (82/420) were considered recovered when they had absence of fever (<37.6 °C) and no sore throat reported in the diary. We defined no sore throat symptoms as no or mild reported sore throat symptoms [12, 13]. According to this definition, another 27 patients were eligible for analysis, resulting in 365 patients available for analysis.

When analysing specific side effects, patients were excluded if no data were registered in the diary or if the patient reported side effects on the day of inclusion. Of the 420 patients, 34 did not answer the question about adverse events (diarrhoea, nausea or vomiting, and rash) at all. Of the 269 women, 37 did not answer the question regarding vaginal itching or discharges.

Statistical methods

Categorical variables were presented as numbers and percentages, and comparisons between groups were made with Pearson’s chi-squared test or Fisher’s exact test. Continuous variables were presented, unless stated otherwise, as median, minimum, and maximum and were compared with the Mann–Whitney U test.

We analysed time to self-reported recovery, time to relief of the single symptom sore throat and the symptom fever, days using painkillers, absence from work or school between the four groups using the log rank test. The two groups with CS-3 were compared and the same comparisons were made between the groups with CS-4. Data were censored on the first day of symptom free recording for the variables self-reported recovery, sore throat, fever and pain, if the symptom relief persisted at least two days. Safety was presented using descriptive statistics. We set the level of significance to 5%, two sided. We performed all analyses using SPSS statistics version 27.0.1.0.

Result

The 420 patients were divided into four groups: CS-3 1 g × 3 10 days, CS-3 800 mg × 4 5 days, CS-4 1 g × 3 10 days, and CS-4 800 mg × 4 5 days. Baseline data were comparable between the groups except for severity of throat pain, which showed a statistically significant difference between the four groups (Table 1). Compared with patients with CS-3, more patients with CS-4 rated their throat pain as severe (p = 0.0017).

There was no significant difference in missing data regarding self-reported recovery or sore throat as a single symptom in the diaries between the four groups (p = 0.70 and p = 0.50). According to the patients’ diaries, time to first day of self-reported recovery was significantly shorter in the 5-day treatment group compared with the 10-day treatment group, irrespective if the patient had CS-3 (p = 0.007) or CS-4 (p < 0.001) (Fig. 1). The median number of days to recovery was 4 (1–18) days in the CS-3 10-day group, 3 days (1–10) in the CS-3 5-day group, 4 days (1–18) in the CS-4 10-day group, and 3 days (1–13) in the CS-4 5-day group.

The throat pain as single symptom relieved earlier among patients in the CS-4 5-day treatment group compared with the CS-4 10-day treatment group (p < 0.001); however, for those with CS-3, there were no significant differences in number of days to relief of throat pain between the treatment groups (p = 0.20) (Fig. 2).

On the day of inclusion (day 0), 73% of the patients in the CS-4 5-day group, 67% in the CS-4 10-day group, 59% in the CS-3 5-day group, and 60% in the CS-3 10-day group rated their throat pain as severe (Table 2). The median time with reported severe and moderate pain was two days in all groups except in CS-4 10-day group, where the median time with severe or moderate pain was 3 days.

At the inclusion visit, 84% in CS-4 5-day group and 86% in CS-4 10-day group used pain relievers. The proportion of patients with CS-4 taking pain relievers decreased faster in the group taking PcV four times a day compared with patients taking PcV three times a day (p < 0.001), and 76% in CS-3 5-days group and 72% in the CS-3 10-day group used pain relievers at inclusion (p = 0.14).

There was no difference between the groups in number of days to relief of fever recorded in patients’ diaries (CS-3 5-days vs. 10-days, p = 0.62; CS-4 5-days vs. 10-days, p = 0.67) and no differences between the groups regarding the return to work or school (CS-3, p = 0.90, CS-4, p = 0.70). There were no differences in days of self-reported recovery and in severity of sore throat in children (6–≤ 11 years) regardless of CS and treatment regimen.

After self-reported recovery from infection, 5% reported recurrence of sore throat-related illness. Table 3 presents the number of patients with new symptoms, days to recurrence of sore throat-related symptoms, duration of sore throat-related symptoms, bacterial eradication, and new acute pharyngotonsillitis within a month. No significant differences were found between the groups, except for higher bacterial eradication for the CS-3 10-day group (Table 3).

Bacterial isolates from 40 patients without bacteriological eradication at the follow-up visit were emm-typed. 14 different emm-types were identified. The most common emm-types were 1, 4, 12, 89, and 28, constituting 71% of the tested isolates at inclusion. One isolate was not possible to classify. There were no differences in distribution of emm-types between the groups with CS-3 and CS-4 (p = 0.38). At follow-up,
three isolates were not possible to classify. In 34/36 patients, we found the same emm-type at the follow-up visit as at the inclusion visit.

There was no significant difference in dropouts for side effect registration between the groups. Some patients reported side effects on day of inclusion (day 0): 20/420 diarrhoea; 56/420 nausea or vomiting; 11/420 rash; and 12/269 vaginal itching or discharge. Self-reported side effects were mainly diarrhoea, nausea, or vomiting and vaginal itching and discharge (Table 4). No significant differences between the groups were found.

### Table 1  Baseline characteristics for the population (n = 420) divided into groups based on Centor Score (3 or 4) and given treatment (Penicillin V 800 mg × 4 for 5 days or Penicillin V 1 g × 3 for 10 days) according to the physicians report

|                         | CS-3 1 g × 3 10 days n = 104 | CS-3 800 mg × 4 5 days n = 104 | CS-4 1 g × 3 10 days n = 105 | CS-4 800 mg × 4 5 days n = 107 | p-value* |
|-------------------------|------------------------------|--------------------------------|-------------------------------|--------------------------------|----------|
| **Women**               | 71 (68)                      | 65 (62)                        | 61 (59)                       | 72 (67)                        | 0.39     |
| **Age in years: median (range)** | 30 (3–67)                  | 30 (6–73)                      | 31 (7–63)                     | 30 (7–57)                      | 0.29     |
| **Age group**           |                              |                                |                               |                                |          |
| ≤ 11                    | 13 (13)                      | 19 (18)                        | 14 (13)                       | 19 (18)                        |          |
| 12–17                   | 10 (10)                      | 10 (10)                        | 13 (12)                       | 13 (12)                        |          |
| ≥ 18                    | 81 (78)                      | 75 (72)                        | 78 (74)                       | 81 (76)                        | 0.19     |
| **Weight (kg): median (range)** | 68 (12.5–130)              | 65 (18–114)                    | 70 (21–126)                   | 68 (27–116)                    | 0.19     |
| **Smoker**              | 9 (9)                        | 8 (8)                          | 5 (5)                         | 11 (10)                        | 0.63     |
| **Fever ≥ 38.5 °C**     | 56 (54)                      | 50 (48)                        | 105 (100)                     | 107 (100)                      |          |
| **Tender lymph nodes**  | 83 (80)                      | 92 (89)                        | 104 (100)                     | 107 (100)                      |          |
| **Coating of the tonsils** | 80 (77)                    | 74 (71)                        | 105 (100)                     | 107 (100)                      |          |
| **No cough**            | 80 (89)                      | 74 (92)                        | 105 (100)                     | 107 (100)                      |          |
| **Positive culture for GAS at inclusion visit** | 84 (81)                  | 92 (89)                        | 91 (87)                       | 99 (92)                        | 0.13     |
| **Days with throat pain before inclusion visit, median (range)** | 3 (1–15)                  | 3 (1–14)                       | 3 (1–30)                      | 3 (1–13)                       | 0.44     |
| **Throat pain according to the patient** |                         |                                |                               |                                |          |
| Mild                    | 2 (2)                        | 5 (5)                          | 5 (5)                         | 3 (3)                          |          |
| Moderate                | 49 (47)                      | 46 (44)                        | 31 (30)                       | 33 (31)                        | 0.048    |
| Severe                  | 53 (51)                      | 53 (51)                        | 69 (65)                       | 71 (66)                        |          |
| **General condition according to the physician** |                         |                                |                               |                                |          |
| Mildly affected         | 41 (39)                      | 35 (34)                        | 28 (27)                       | 30 (28)                        |          |
| Moderately affected     | 63 (61)                      | 69 (66)                        | 77 (73)                       | 77 (72)                        | 0.18     |
| **Impact of the infection** |                                     |                                |                               |                                |          |
| Ability to eat and drink| 89 (86)                      | 86 (83)                        | 96 (91)                       | 96 (90)                        | 0.22     |
| Sleep                   | 78 (75)                      | 83 (81)                        | 85 (80)                       | 85 (80)                        | 0.75     |
| General condition       | 86 (83)                      | 92 (89)                        | 91 (87)                       | 99 (92)                        | 0.30     |
| Daily activity          | 88 (85)                      | 86 (83)                        | 94 (80)                       | 96 (90)                        | 0.65     |
| Days (median)           | 2                            | 2                              | 2                             | 2                              | 0.23     |
| Tonsillectomized        | 4 (4)                        | 3 (3)                          | 3 (3)                         | 2 (2)                          | 0.86     |
| > 3 antibiotic-treated tonsillitis last year | 3 (3)                  | 1 (1)                          | 1 (1)                         | 3 (3)                          | 0.52     |
| Children < 18 years in the household | 74 (71)                 | 79 (76)                        | 77 (73)                       | 81 (76)                        | 0.62     |
| Ongoing throat infection in family or related | 30 (29)                  | 24 (23)                        | 32 (31)                       | 35 (33)                        | 0.60     |

Values are numbers (percentages) unless stated otherwise

*Comparison between the four groups

### Discussion

In this prospective clinical study of patients with phar-yngotonsillitis with group A streptococci, patients with CS-3 as well as CS-4 who received PcV 800 mg × 4 for 5 days reported recovering earlier than those who received treatment with PcV 1 g × 3 for 10 days. In addition, throat pain as a single symptom was relieved earlier (1 day) and the period the patient used painkill-ers was shorter in patients with CS-4 who received PcV 800 mg × 4 for 5 days compared to those who received standard treatment with PcV 1 g × 3 for 10 days. For
Fig. 1  Time to first day of self-reported recovery according to patients' diaries for patients with Centor Score of 3 or 4 and 5 or 10 days with PcV treatment, respectively

Fig. 2  Time to first day of reporting mild or no pain in the throat according to patients' diaries for patients with Centor Score 3 or 4 and 5 or 10 days with PcV treatment

Table 2  Proportion (%) of patients with severe, moderate, mild or no throat pain according to patients' diaries for the 420 patients divided into groups based on Centor Score (3 or 4) and given treatment (Penicillin V 800 mg × 4 for 5 days or Penicillin V 1 g × 3 for 10 days)

| Day | CS-3 1 g × 3, 10 days n = 104 | CS-3 800 mg × 4, 5 days n = 104 | CS-4 1 g × 3, 10 days n = 105 | CS-4 800 mg × 4, 5 days n = 107 |
|-----|--------------------------------|---------------------------------|-------------------------------|-------------------------------|
|     | Severe | Moderate | Mild | No | Severe | Moderate | Mild | No | Severe | Moderate | Mild | No | Severe | Moderate | Mild | No |
| 0   | 60     | 36       | 3    |   | 59     | 33       | 2    |   | 67     | 18       | 6    |   | 73     | 21       | 6    |   |
| 1   | 29     | 45       | 23   |   | 31     | 41       | 24   | 4  | 48     | 32       | 18   | 2  | 26     | 50       | 24   | 1  |
| 2   | 9      | 36       | 38   | 17 | 7      | 30       | 43   | 19 | 18     | 39       | 32   | 12 | 4      | 34       | 48   | 14 |
| 3   | 5      | 14       | 48   | 33 | 3      | 8        | 50   | 39 | 9      | 21       | 39   | 31 | 1      | 10       | 44   | 45 |
| 4   | 2      | 10       | 35   | 53 | 2      | 1        | 32   | 65 | 2      | 14       | 36   | 48 | 0      | 3        | 28   | 69 |
| 5   | 4      | 3        | 25   | 68 | 1      | 1        | 14   | 84 | 0      | 10       | 28   | 63 | 0      | 1        | 20   | 79 |
| 6   | 2      | 4        | 18   | 76 | 0      | 3        | 8    | 89 | 1      | 3        | 23   | 72 | 0      | 3        | 12   | 86 |
| 7   | 1      | 3        | 12   | 84 | 0      | 1        | 13   | 86 | 0      | 3        | 11   | 87 | 1      | 1        | 16   | 82 |
| 8   | 1      | 1        | 9    | 90 | 1      | 3        | 10   | 86 | 0      | 1        | 11   | 88 | 1      | 5        | 13   | 80 |
| 9   | 1      | 1        | 8    | 91 | 0      | 4        | 10   | 86 | 0      | 2        | 4    | 94 | 0      | 10       | 14   | 77 |
| 10  | 1      | 1        | 7    | 91 | 0      | 5        | 8    | 88 | 0      | 2        | 4    | 94 | 2      | 4        | 13   | 81 |
for either 5 or 10 days, more bacteriologic failures were found in the 5-day than in the 10-day treatment groups. However, in these studies, the CS was not used and the PcV daily dosages were lower than in our study [16, 17]. In an RCT by Zwart, where patients with CS-3 or -4 were considered one group, the regression of symptoms was faster in the 7-day than in the 3-day treatment group, but there were no differences in number of re-consultations [14].

A recently published review concluded that long-course PcV should remain the first line antibiotic for the management of patients with streptococcal pharyngitis [8]; however, most of the studies comparing the duration of treatment with PcV were based on a three dose per day regimen and compared long-term antibiotic therapy (10 days PcV) with short-term broad-spectrum antibiotics. In our previous study, we showed that PcV four times daily for 5 days was non-inferior in clinical cure to PcV three times daily for 10 days in patients with pharyngotonsillitis with CS-3 or -4 and diagnosed with GAS. The subgroup analyses indicated lower clinical cure with the 5-day regime in the CS-4 group. These results were based on data from the per-protocol population and the test of cure visit [10]. In the present study, data were based on

| Table 3 | Clinical course after completed PcV treatment for the 420 patients divided into groups based on Centor Score (3 or 4) and given treatment (Penicillin V 800 mg × 4 for 5 days or Penicillin V 1 g × 3 for 10 days) |
|---------|---------------------------------------------------------------------------------------------------------------|
|         | 3-CS 1 g × 3, 10 days n = 104 | 3-CS 800 mg × 4, 5 days n = 104 | p | 4-CS 1 g × 3, 10 days n = 105 | 4-CS 800 mg × 4, 5 days n = 107 | p |
| Patients with new sore throat related illness* n (%) | 3 (3) | 8 (8) | 0.19 | 3 (3) | 7 (7) | 0.17 |
| Days to recurrence of sore throat-related illness* (median) | 1 | 1.5 | 0.82 | 1 | 2 | 0.12 |
| Duration of the sore throat- related illness* (median) | 2 | 3 | 0.81 | 3 | 3 | 0.39 |
| Bacterial eradication at follow-up visit n (%) | 84 (81) | 78 (75) | 0.03 | 81 (77) | 82 (77) | 0.29 |
| New acute pharyngotonsillitis within one month n (%) | 5 (5) | 10 (10) | 0.20 | 6 (6) | 13 (12) | 0.10 |

* Based on patients’ diaries

| Table 4 | Self-reported adverse events according to the patients’ diaries divided into groups based on Centor Score (3 or 4) and given treatment (Penicillin V 800 mg × 4 for 5 days or Penicillin V 1 g × 3 for 10 days) |
|---------|---------------------------------------------------------------------------------------------------------------|
|         | CS-3 1 g × 3, 10 days n = 104 | CS-3 800 mg × 4, 5 days n = 104 | CS-4 1 g × 3, 10 days n = 105 | CS-4 800 mg × 4, 5 days n = 107 |
| Diarrhoea | 29 (28) | 21 (20) | 25 (24) | 22 (21) |
| No (%) | Duration (days)* | No (%) | Duration (days)* | No (%) | Duration (days)* | No (%) | Duration (days)* |
| Nausea or vomiting | 11 (11) | 15 (11) | 10 (10) | 6 (9) |
| Vaginal itching or discharge (women) | 15 (21) | 7 (10) | 10 (14) | 1 (1) |
| Rash | 5 (5) | 5 (5) | 6 (6) | 1 (1) |

* Median (interquartile range)
the intention to treat population and self-reported data in patient diaries, so it measures a more patient-related outcome.

The present study shows that the shorter four dose treatment regime seems to be beneficial regardless of CS-3 or CS-4, and patients report a faster overall recovery from infection with the shorter (5 days) and more intense treatment. Also, the number of days with severe to moderate throat pain was reduced faster among those with CS-4 when taking antibiotics four times a day. This finding is also supported by the fact that duration of analgesic use was shorter in the CS-4 5-day group. One likely explanation for the efficacy of the 5-day treatment is the longer time above MIC due to more frequent dosage [19]. This result answers the research question raised in the Cochrane review [8]. Furthermore, we found no differences in re-consultations within a month between the four groups. The present study is not powered to identify differences in re-consultation rates, therefore it should be relevant to investigate in further studies. The different results from test of cure and diaries may also be due to new sore throat symptoms at the test of cure, symptoms that do not necessarily lead to a re-consultation.

In many studies investigating sore throat, symptom reduction is the main outcome, which from a clinical perspective seems relevant since GAS can be present in healthy persons [20, 21]. As far as we know, this is the first study that shows that patients with more symptoms (i.e., patients with CS-4) benefit the most from a shorter but more intensive treatment strategy. Although the benefits are not as great for the patients in the CS-3 group, they also experience a shorter disease period with the more intense 5-day treatment.

We do not know why the severity of the symptoms varies, but it has been debated if the enm-type of GAS is important [22]. The enm-types vary over time with age group, and some studies have found that specific enm-types are more common in pharyngitis [23, 24], but this could not be confirmed in others [25]. The same enm-type can be found in both invasive and non-invasive diseases [26]. In the present study, the enm-types are similar to the most frequently isolated enm-types from invasive cases in Sweden during the study period [27], a finding that indicates factors other than enm-types influence severity.

Our previous study found that a shorter but more intense treatment regimen of PcV led to fewer side effects and a shorter duration of side effects [10]. This finding could be explained by a shorter exposure of PcV. This pattern was the same when divided by CS. The finding that there were fewer side effects with shorter duration in the 5-day group further strengthens the 5-day treatment strategy. A longer treatment period also gives higher antibiotic selection pressure, which increases the risk of resistance in society [1].

Empirical evidence of antibiotic treatment for children with pharyngotonsillitis is scarce according to a Cochrane review [15]. Zwart et al., comparing the effect of penicillin for 3 days, 7 days, and a placebo in children with sore throat, found that penicillin treatment had no beneficial effect on the average duration of symptoms [18]. In our study, we found that there were no differences in self-reported recovery and severity of sore throat in children (6–11 years) regardless of CS and treatment regimen. Although the study was not powered for subgroup analysis in children, it raises the question of how much children with sore throat benefit from antibiotic treatment.

Overall, the results indicate that there are several benefits with 4-dose regimen for 5 days compared to the Swedish standard treatment, 3-dose regimen for 10 days, both among patients with CS-3 and CS-4. The intense treatment reduces the amount of PcV for every treatment against pharyngotonsillitis, from 30 g PcV to 16 g. This means a yearly reduction of almost 50% in antibiotic pressure for this indication in Sweden.

Strengths and limitations
This study examines everyday clinical practice as we used inclusion criteria in line with current treatment guidelines and dosage regimens according to modern knowledge of pharmacokinetics and pharmacodynamics. As the diaries had a high response rate, we gathered the patient’s own assessment of symptoms and not just the doctor’s assessment. Another strength is that children were included in the study because they are often treated with antibiotics for respiratory tract infections in primary healthcare [3, 28]. In addition we performed enm-typing on those not bacteriological eradicated at the follow-up visit. This enhances the generalizability of the study by showing that the GAS found in the patients in our study are similar to those circulating in the society.

A limitation is that not all GAS isolates were enm-typed, so we cannot say if the distribution is the same in the CS-3 and CS-4 groups. In addition, the patients were aware of which dose regimen they received and this could have affected the reporting. Another limitation is that some diaries were not complete, but there were no significant differences in missing data between the groups.

Conclusion
Intense treatment with PcV 4 times per day for 5 days seems clinically beneficial compared to the Swedish standard treatment (PcV 3 times per day for 10 days) when treating CS-3 and CS-4 patients with GAS positive pharyngotonsillitis. Both groups experienced a faster
overall self-reported recovery; for patients with CS-4, the intense treatment also shortened the period of throat pain. A reduction of 14 g PcV in every treatment, no difference in relapses, and side effects further strengthens the suggestion that the 4-dose regimen with 800 mg PcV for 5 days may be the future treatment strategy for GAS positive pharyngotonsillitis.

Abbreviations
GAS: Group A streptococci; CS: Centor Score; PcV: Phenoxymethylpenicillin; RADT: Rapid antigen detection test; ESCMID: European Society of Clinical Microbiology and Infectious Diseases.

Acknowledgements
We thank the patients participating in the trial and the study personnel at the participating primary healthcare centres: Bo Roland at Futurum, Region Jönköping County for statistical advice and Jessica Darenberg for emm-typing, Unit for Laboratory Surveillance of Bacterial Pathogens, Department of Microbiology, The Public Health Agency of Sweden. Participating primary healthcare centres (investigator), regional study nurses, and microbiological laboratories: Region Skåne: Lodeköpinge värdcentral (Anders Walldén); Capio Citykliniken Malmö Linhamn (Ulla Wikstrom); Sorgenfrimottagningen (Lisa Edborsson Klemendz); Värdcentralen Lundbergsigan (Mia Tyrstrup); Värdcentralen Sjöbo (Mikael Karlsson); Capio Citykliniken Bunkeflo Hylle (Oskar Smede); regional study nurse Emma Lundström; Läkemedicin Skåne. Region Kronoberg: Alвестa värdcentral (Mattias Rööst); Capio värdcentralen HVshaga (Yasir Mahdi); Värdcentralen Lessebo (Robert Zuccconi); Värdcentralen Strandbäckert (Johanna Sandgren); regional study nurse Catharina Lindqvist; Klinisk mikrobiologi i Växjö; Vastra Gotalandsregionen, Närhälsan Sandared (Pär‑Daniel Sundvall); Närhälsan Fristad (Gudrun Greim); Närhälsan Bollebygd (Helena Kårestedt); Närhälsan Södra Ryd (Karin Rystedt); Närhälsan Billingent (Emma Otterd); Närhälsan Normalm (Micael Elmersson); regional study nurse Sofia Sundvall; Klinisk mikrobiologi, Sahlgrenska Universitetssjukhuset and Unilabs AB, Skövde; Region Södermanland: Strängnäs värdcentral (Per Westberg); Unilabs AB, Eskilstuna.

Author contributions
DT, MT, CE, KR, GSS, PDS, and KH contributed to study design. MT, KR, PDS, and KH contributed to the acquisition of data. DT and KH performed the analysis and interpreted data and wrote the first draft of the text. All authors were involved in revising the text, especially for important intellectual content, approved the final manuscript.

Funding
The study was funded by the Public Health Agency of Sweden and Region Jönköping County.

Availability of data and materials
The data sets generated and analysed during the current study are not publicly available due to Swedish legislation (the Personal Data Act) but are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the Regional Ethical Review board in Lund on 25 June 2015 (reference number 2015/396) and were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all participants and/or their legal guardian before inclusion and participants could withdraw at any time.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 21 April 2022 Accepted: 1 November 2022
Published online: 11 November 2022

References
1. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet (London, England). 2005;365(9459):579–87.
2. Bruyndonckx R, Adriaenssens N, Versporten A, Hens N, Monnet DL, Molenberghs G, Goossens H, West K, Coenen S. Consumption of antibiotics in the community, European Union/European Economic Area, 1997–2017. J Antimicrob Chemotherapy. 2021;76(12 Suppl 2):i7–13.
3. Tyrstrup M, Beckman A, Mølstad S, Engstrom S, Lannering C, Melander E, Hedén K. Reduction in antibiotic prescribing for respiratory tract infections in Swedish primary care - a retrospective study of electronic patient records. BMC Infect Dis. 2016;16(1):709.
4. Peluchi C, Grigoryan L, Galeone C, Esposito S, Huovinen P, Little P, Verheij T. Guideline for the management of acute sore throat. Clin Microbiol Infect. 2012;18(Suppl 1):1–28.
5. Sweden MPo. The management of pharyngotonsillitis in outpatient care [Handläggning av faryngotonsillit i öppenvård]. Information från läkemedelsverket. 2012;3(8):16–66.
6. Centor RM, Witherspoon JM, Dalton HP, Brody CE, Link K. The diagnosis of strep throat in adults in the emergency room. Med Decis Mak. 1997;17(3):239–46.
7. Altamimi S, Khalil A, Khalawi KA, Milner RA, Pusic MV, Othman MA. Short-term late-generation antibiotics versus longer term penicillin for acute streptococcal pharyngitis in children. Cochrane Database Syst Rev. 2012. https://doi.org/10.1002/14651858.CD004872.pub3.
8. Holm AE, Llor C, Bjernum L, Cordoba G. Short- vs. long-course antibiotic treatment for acute streptococcal pharyngitis: systematic review and meta-analysis of randomized controlled trials. Antibiotics (Basel, Switzerland). 2020;9(11):733.
9. Skoog Ståhlgren G, Tyrstrup M, Edlund C, Giske CG, Mølstad S, Norman C, Rystedt K, Sundvall PD, Hedén K. Penicillin V four times daily for five days versus three times daily for 10 days in patients with pharyngotonsillitis caused by group A streptococci: randomised controlled, open label, non-inferiority study. BMJ (Clinical research ed). 2019;367:l5337.
10. Beall B, Facklam R, Thompson T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol. 1996;34(4):953–8.
11. Little P, Hobbs FD, Moore M, Mant D, Williamson I, McNulty C, Cheng YE, Leydon G, McManus R, Kelly J, et al. Clinical score and rapid antigen detection test to guide antibiotic use for sore throats: randomised controlled trial of PRISM (primary care streptococcal management). BMJ (Clinical Research ed). 2013;347:f5806.
12. Moore M, Stuart B, Hobbs FR, Butler CC, Hay AD, Campbell J, Delaney BC, Broomfield S, Barratt P, Hood K, et al. Influence of the duration of penicillin prescriptions on outcomes for acute sore throat in adults: the DESCARTE prospective cohort study in UK general practice. Br J Gen Pract. 2017;67(662):e623–33.
13. Zwart S, Sachs AP, Ruijs GJ, Gubbels JW, Hoes AW, de Melker RA. Penicillin for acute sore throat: randomised double blind trial of seven days versus three days treatment or placebo in adults. BMJ (Clinical Research ed). 2000;320(7228):150–4.
15. Spinks A, Glasziou PP, Del Mar CB. Antibiotics for sore throat. Cochrane Database Syst Rev. 2013;2013(1):CD000023.
16. Gerber MA, Randolph MF, Chanaty J, Wright LL, DeMeo K, Kaplan EL. Five vs ten days of penicillin V therapy for streptococcal pharyngitis. Am J Dis Child (1960). 1967;141(2):224–7.
17. Strömberg A, Schwab A, Cars O. Five versus ten days treatment of group A streptococcal pharyngotonsillitis: a randomized controlled clinical trial with phenoxymethylpenicillin and cefadroxil. Scand J Infect Dis. 1988;20(1):37–46.
18. Zwart S, Rovers MM, de Melker RA, Hoes AW. Penicillin for acute sore throat in children: randomised, double blind trial. BMJ. 2003;327(7427):1324.
19. Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, MacGowan A, Theuretzbacher U, Turnidge J. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updates. 2011;14(2):107–17.
20. Oliver J, Mallyya Wadu E, Pierse N, Moreland NJ, Williamson DA, Baker MC. Group A Streptococcus pharyngitis and pharyngeal carriage: a meta-analysis. PLoS Negl Trop Dis. 2018;12(3): e0006335.
21. Hedin K, Bieber L, Lindh M, Sundqvist M. The aetiology of pharyngotonsillitis in adolescents and adults—Fusobacterium necrophorum is commonly found. Clin Microbiol Infect. 2015;21(3):263.e261–267.
22. Schmitz FJ, Beyer A, Charpentier E, Normark BH, Schade M, Fluit AC, Hafner D, Novak R. Toxic-gene profile heterogeneity among endemic invasive European group A streptococcal isolates. J Infect Dis. 2003;188(10):1578–86.
23. Tamayo E, Montes M, García-Arenzana JM, Pérez-Trallero E. Streptococcus pyogenes emm-types in northern Spain; population dynamics over a 7-year period. J Infect. 2014;68(1):50–7.
24. d’Humières C, Bidet P, Levy C, Béchet S, Bonacorsi S, Bingen E, Cohen R. Comparative epidemiology of Streptococcus pyogenes EMM-types causing invasive and noninvasive infections in French children by use of high-resolution melting-polymerase chain reaction. Pediatr Infect Dis J. 2015;34(6):557–61.
25. Chang H, Shen X, Huang G, Fu Z, Zheng Y, Wang L, Li C, Liu L, Shen Y, Liu X, et al. Molecular analysis of Streptococcus pyogenes strains isolated from Chinese children with pharyngitis. Diagn Microbiol Infect Dis. 2011;69(2):117–22.
26. Su YF, Wang SM, Lin YL, Chuang WJ, Lin YS, Wu JJ, Lin MT, Liu CC. Changing epidemiology of Streptococcus pyogenes EMM types and associated invasive and noninvasive infections in Southern Taiwan. J Clin Microbiol. 2009;47(8):2658–61.
27. Invasive group A streptococcal disease, seasonal report 2016–2017 [https://www.folkhalsomyndigheten.se/publicerat-material/publikatio nsarkiv/invasiva-grupp-a-streptokocker-sasongsrapport-2016-2017/]
28. Bou-Antoun S, Costelloe C, Honeyford K, Mazidi M, Hayhoe BWJ, Holmes A, Johnson AP, Aylin P. Age-related decline in antibiotic prescribing for uncomplicated respiratory tract infections in primary care in England following the introduction of a national financial incentive (the Quality Premium) for health commissioners to reduce use of antibiotics in the community: an interrupted time series analysis. J Antimicrob Chemother. 2018;73(10):2883–92.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.